Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.
Kathryn E. Hudson, MD, hematologist and oncologist, director, Survivorship for Texas Oncology, Texas Oncology, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.
Liquid biopsies are emerging as a more common option used by oncologists to test for biomarkers, though their acceptance is limited by lack of data, explains Hudson. Additionally, there are no large panel liquid biopsy tests currently approved by the FDA.
Currently, tumor tissue is the most standard and well-accepted way to perform molecular testing; however, liquid biopsies are available to get information should a tissue biopsy not be possible, concludes Hudson.